Darwin Global Management, Ltd. Allogene Therapeutics, Inc. Transaction History
Darwin Global Management, Ltd.
- $2.37 Billion
- Q2 2025
A detailed history of Darwin Global Management, Ltd. transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Darwin Global Management, Ltd. holds 10,479,791 shares of ALLO stock, worth $10.8 Million. This represents 0.5% of its overall portfolio holdings.
Number of Shares
10,479,791
Previous 10,449,791
0.29%
Holding current value
$10.8 Million
Previous $15.3 Million
22.38%
% of portfolio
0.5%
Previous 1.06%
Shares
2 transactions
Others Institutions Holding ALLO
# of Institutions
171Shares Held
165MCall Options Held
146KPut Options Held
97.1K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$19.3 Million1.28% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$16.9 Million0.0% of portfolio
-
Capital World Investors Los Angeles, CA11.2MShares$11.5 Million0.0% of portfolio
-
Lynx1 Capital Management LP San Juan, PR11.1MShares$11.4 Million3.7% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il10.3MShares$10.6 Million0.0% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $148M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...